BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21401887)

  • 1. Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target.
    Fontana V; Silva PS; Belo VA; Antonio RC; Ceron CS; Biagi C; Gerlach RF; Tanus-Santos JE
    Basic Clin Pharmacol Toxicol; 2011 Aug; 109(2):130-7. PubMed ID: 21401887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction.
    Muniz JJ; Lacchini R; Belo VA; Nobre YT; Tucci S; Martins AC; Tanus-Santos JE
    Int J Impot Res; 2012; 24(1):38-43. PubMed ID: 21918531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
    Belo VA; Souza-Costa DC; Lana CM; Caputo FL; Marcaccini AM; Gerlach RF; Bastos MG; Tanus-Santos JE
    Clin Biochem; 2009 Jul; 42(10-11):984-90. PubMed ID: 19358835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fosinopril and valsartan intervention in gene expression of Klotho, MMP-9, TIMP-1, and PAI-1 in the kidney of spontaneously hypertensive rats.
    Cheng X; Zhou Q; Lin S; Wu R
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Oct; 35(10):1048-56. PubMed ID: 21051829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amlodipine and Atorvastatin Improved Hypertensive Cardiac Remodeling through Regulation of MMPs/TIMPs in SHR Rats.
    Lu J; Hao J; Du H; Xiao B; Li Y; Yang X; Cui W
    Cell Physiol Biochem; 2016; 39(1):47-60. PubMed ID: 27322513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.
    Gonçalves FM; Jacob-Ferreira AL; Gomes VA; Casella-Filho A; Chagas AC; Marcaccini AM; Gerlach RF; Tanus-Santos JE
    Clin Chim Acta; 2009 May; 403(1-2):173-7. PubMed ID: 19254704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension.
    Palei AC; Sandrim VC; Cavalli RC; Tanus-Santos JE
    Clin Biochem; 2008 Jul; 41(10-11):875-80. PubMed ID: 18477480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
    Derosa G; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo S; Montagna L; Gravina A; Ferrari I; Galli S; Paniga S; Tinelli C; Cicero AF
    Endothelium; 2006; 13(3):227-31. PubMed ID: 16840178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of matrix metalloproteinases in patients with Wegener's granulomatosis.
    Bjerkeli V; Halvorsen B; Damås JK; Nordøy I; Yndestad A; Aukrust P; Frøland SS
    Ann Rheum Dis; 2004 Dec; 63(12):1659-63. PubMed ID: 15547092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced systemic matrix metalloproteinase response in Helicobacter pylori gastritis.
    Rautelin HI; Oksanen AM; Veijola LI; Sipponen PI; Tervahartiala TI; Sorsa TA; Lauhio A
    Ann Med; 2009; 41(3):208-15. PubMed ID: 18979291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats.
    Zhang X; Sakamoto T; Hata Y; Kubota T; Hisatomi T; Murata T; Ishibashi T; Inomata H
    Exp Eye Res; 2002 May; 74(5):577-84. PubMed ID: 12076079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Significance of imbalance between matrix metalloproteinases and tissue type inhibitor of metalloproteinases in renal tubulointerstitial lesions of aging rats].
    Chen RQ; Chen XM; Cui SW; Cai GY; Shi SZ; Xie YS; Lu Y; Peng LX
    Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):937-42. PubMed ID: 15329283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACE inhibition reduces activity of the plasminogen/plasmin and MMP systems in the brain of spontaneous hypertensive stroke-prone rats.
    Liebetrau M; Burggraf D; Wunderlich N; Jäger G; Linz W; Hamann GF
    Neurosci Lett; 2005 Mar; 376(3):205-9. PubMed ID: 15721222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and response to angiotensin-converting enzyme inhibition of matrix metalloproteinases 2 and 9 in renal glomerular damage in young transgenic rats with renin-dependent hypertension.
    Bolbrinker J; Markovic S; Wehland M; Melenhorst WB; van Goor H; Kreutz R
    J Pharmacol Exp Ther; 2006 Jan; 316(1):8-16. PubMed ID: 16166267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of tissue inhibitor of metalloproteases-1 (TIMP-1) and procollagen-N-peptidase in hypertension-induced renal damage.
    Hultström M; Leh S; Skogstrand T; Iversen BM
    Nephrol Dial Transplant; 2008 Mar; 23(3):896-903. PubMed ID: 17977875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
    Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
    Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term MMP inhibition by doxycycline exerts divergent effect on ventricular extracellular matrix deposition and systolic performance in stroke-prone spontaneously hypertensive rats.
    Zeng S; Zhou X; Tu Y; Yao M; Han ZQ; Gao F; Li YM
    Clin Exp Hypertens; 2011; 33(5):316-24. PubMed ID: 21649529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
    Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
    Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
    Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z
    Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.